Indian equities rallied sharply as an interim US-Iran peace framework eased geopolitical concerns and pushed oil prices lower. Improved inf...

Flexi cap fund inflows dropped 49% in May to Rs 5,175 crore after April’s record surge, reflecting broader moderation across equity categor...

Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced i...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

Quant Mid Cap Fund exited Lenskart Solutions, NMDC and SBI Cards in April, while adding Steel Authority of India to its portfolio, the fund...

Bajaj Auto has announced that its board will consider a share buyback proposal on May 6, 2026, signalling plans to return surplus cash to s...

In today's trade, shares of SBI Life, Trent, Tata Investment, HCL Tech, Suzlon Energy among others will be in focus due to various news dev...

Aurobindo Pharma has announced an Rs 800 crore share buyback via the tender route, offering Rs 1,475 per share. The buyback opens April 23 ...

Aurobindo Pharma has announced an ₹800-crore buyback at ₹1,475 per share, with April 17, 2026 set as the record date—meaning investors must...

Four companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo...

Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing ...

Following the development, Aurobindo Pharma’s counter touched a 52-week low of Rs 581 on the BSE. The scrip had closed at Rs 603.05 on Tues...

Tondon said that he would not be surprised if the stock rallies further. He expects the US FDA clearance to make sure that earnings meet ex...

We had a positive coverage on Aurobindo Pharma. Post this news we need to go back to our working table and have a re-look on our stance ove...

"Aurobindo Pharma has been smashed a bit on news. The news is old or new but then the fact remains that the market has actually chosen to h...

Aurobindo Pharma corrected fairly sharply on the news, and Rs 155-160 is now a good base for Aurobindo Pharma. On the upside, it will face ...

165-170 is kind of the base for Aurobindo and from there it should rally back towards 215-220.